{"protocolSection": {"identificationModule": {"nctId": "NCT01023581", "orgStudyIdInfo": {"id": "SYR-322MET_302"}, "secondaryIdInfos": [{"id": "2009-012652-24", "type": "REGISTRY", "domain": "EudraCT"}, {"id": "U1111-1112-1912", "type": "REGISTRY", "domain": "WHO"}, {"id": "DOH-27-0910-3155", "type": "REGISTRY", "domain": "SANCTR"}, {"id": "CTRI/2010/091/000253", "type": "REGISTRY", "domain": "CTRI"}], "organization": {"fullName": "Takeda", "class": "INDUSTRY"}, "briefTitle": "Efficacy and Safety of Alogliptin Plus Metformin in Patients With Type 2 Diabetes", "officialTitle": "A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Efficacy and Safety of Alogliptin Plus Metformin, Alogliptin Alone, or Metformin Alone in Subjects With Type 2 Diabetes", "acronym": "AM7D"}, "statusModule": {"statusVerifiedDate": "2013-02", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2009-11"}, "primaryCompletionDateStruct": {"date": "2011-06", "type": "ACTUAL"}, "completionDateStruct": {"date": "2011-06", "type": "ACTUAL"}, "studyFirstSubmitDate": "2009-12-01", "studyFirstSubmitQcDate": "2009-12-01", "studyFirstPostDateStruct": {"date": "2009-12-02", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2013-02-17", "resultsFirstSubmitQcDate": "2013-02-17", "resultsFirstPostDateStruct": {"date": "2013-03-26", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2013-02-17", "lastUpdatePostDateStruct": {"date": "2013-03-26", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Takeda", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": true}, "descriptionModule": {"briefSummary": "The purpose of this study is to evaluate the safety and effectiveness of alogliptin combined with metformin, once daily (QD) or twice daily (BID), in participants with Type 2 Diabetes.", "detailedDescription": "There are approximately 19 million people in the United States who have been diagnosed with diabetes mellitus, of which 90% to 95% are type 2. The prevalence of type 2 diabetes varies among racial and ethnic populations and has been shown to correlate with age, obesity, family history, history of gestational diabetes and physical inactivity. Over the next decade, a marked increase in the number of adults with diabetes mellitus is expected.\n\nMetformin is the usual choice of first-line therapy for type 2 diabetes. Metformin targets insulin resistance in type 2 diabetes by inhibiting hepatic glucose production and stimulating glucose uptake in skeletal muscle and adipose tissue, which results in a long-term glucose-lowering effect.\n\nAlogliptin is an inhibitor of the dipeptidyl peptidase IV enzyme. Dipeptidyl peptidase-4 enzyme is thought to be primarily responsible for the in vivo degradation of 2 peptide hormones released in response to nutrient ingestion, namely glucagon-like peptide-1 and glucose-dependent insulinotropic peptide. Both peptides exert important effects on islet beta cells to stimulate glucose-dependent insulin secretion as well as regulating beta cell proliferation and cytoprotection. Glucagon-like peptide-1, but not glucose-dependent insulinotropic peptide, inhibits gastric emptying, glucagon secretion, and food intake. Glucose-dependent insulinotropic peptide has been shown to enhance insulin secretion by direct interaction with a glucose-dependent insulinotropic peptide -specific receptor on islet beta cells. The glucose-lowering actions of glucagon-like peptide-1, but not glucose-dependent insulinotropic peptide, are preserved in patients with type 2 diabetes mellitus. It is expected that inhibition of dipeptidyl peptidase IV will improve glycemic (glucose) control in patients with type 2 diabetes.\n\nBased on the potential, complimentary mechanisms of action of alogliptin and metformin, this study will compare the safety and efficacy of alogliptin and metformin (SYR-322MET) on improving glycemic control in patients with type 2 diabetes mellitus who are inadequately controlled by diet adjustment and exercise alone.\n\nParticipants taking part in this study will receive dietary and exercise coaching, and will monitor their own blood glucose concentrations with a home glucose monitor. Participants will also be required to maintain a hypoglycemic diary throughout the course of the study. Participation in this study is expected to last up to 34 weeks."}, "conditionsModule": {"conditions": ["Diabetes Mellitus, Type 2"], "keywords": ["Type 2 Diabetes mellitus", "Non-insulin dependent diabetes mellitus", "Drug Therapy", "Hypoglycemia,", "Hyperglycemia"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "QUADRUPLE", "whoMasked": ["PARTICIPANT", "CARE_PROVIDER", "INVESTIGATOR", "OUTCOMES_ASSESSOR"]}}, "enrollmentInfo": {"count": 784, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Placebo", "type": "PLACEBO_COMPARATOR", "description": "Alogliptin placebo-matching tablets, orally, twice daily and Metformin placebo-matching capsules, orally, twice daily for up to 26 weeks.", "interventionNames": ["Drug: Alogliptin Placebo", "Drug: Metformin Placebo"]}, {"label": "Alogliptin 25 QD", "type": "EXPERIMENTAL", "description": "Alogliptin 25 mg, tablets, orally, once daily (QD) and Metformin placebo-matching capsules, orally, twice daily for up to 26 weeks.", "interventionNames": ["Drug: Alogliptin", "Drug: Metformin Placebo"]}, {"label": "Alogliptin 12.5 BID", "type": "EXPERIMENTAL", "description": "Alogliptin 12.5 mg, tablets, orally, twice daily (BID) and Metformin placebo-matching capsules, orally, twice daily for up to 26 weeks.", "interventionNames": ["Drug: Alogliptin", "Drug: Metformin Placebo"]}, {"label": "Metformin 500 BID", "type": "ACTIVE_COMPARATOR", "description": "Alogliptin placebo-matching tablets, orally, twice daily and Metformin 500 mg capsules, orally, twice daily for up to 26 weeks.", "interventionNames": ["Drug: Metformin", "Drug: Alogliptin Placebo"]}, {"label": "Metformin 1000 BID", "type": "ACTIVE_COMPARATOR", "description": "Alogliptin placebo-matching tablets, orally, twice daily and Metformin 1000 mg capsules, orally, twice daily for up to 26 weeks.", "interventionNames": ["Drug: Metformin", "Drug: Alogliptin Placebo"]}, {"label": "Alogliptin 12.5 BID + Metformin 500 BID", "type": "EXPERIMENTAL", "description": "Alogliptin 12.5mg, tablets, orally, twice daily and Metformin 500 mg, capsules, orally, twice daily for up to 26 weeks.", "interventionNames": ["Drug: Alogliptin", "Drug: Metformin"]}, {"label": "Alogliptin 12.5 BID + Metformin 1000 BID", "type": "EXPERIMENTAL", "description": "Alogliptin 12.5 mg, tablets, orally, twice daily and Metformin 1000 mg, capsules, orally, twice daily for up to 26 weeks.", "interventionNames": ["Drug: Alogliptin", "Drug: Metformin"]}], "interventions": [{"type": "DRUG", "name": "Alogliptin", "description": "Alogliptin tablets.", "armGroupLabels": ["Alogliptin 12.5 BID", "Alogliptin 12.5 BID + Metformin 1000 BID", "Alogliptin 12.5 BID + Metformin 500 BID", "Alogliptin 25 QD"], "otherNames": ["SYR-322"]}, {"type": "DRUG", "name": "Metformin", "description": "Metformin capsules", "armGroupLabels": ["Alogliptin 12.5 BID + Metformin 1000 BID", "Alogliptin 12.5 BID + Metformin 500 BID", "Metformin 1000 BID", "Metformin 500 BID"], "otherNames": ["Glucophage", "Glucophage XR", "Riomet", "Fortamet", "Glumetza", "Obimet", "Dianben", "Diabex", "Diaformin"]}, {"type": "DRUG", "name": "Alogliptin Placebo", "description": "Alogliptin placebo-matching tablets.", "armGroupLabels": ["Metformin 1000 BID", "Metformin 500 BID", "Placebo"]}, {"type": "DRUG", "name": "Metformin Placebo", "description": "Metformin placebo-matching capsules.", "armGroupLabels": ["Alogliptin 12.5 BID", "Alogliptin 25 QD", "Placebo"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 26", "description": "The change from Baseline to Week 26 in HbA1c (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound).", "timeFrame": "Baseline and Week 26."}], "secondaryOutcomes": [{"measure": "Change From Baseline in HbA1c Over Time", "description": "The change from Baseline in HbA1c (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) was assessed at Weeks 4, 8, 12, 16 and 20.\n\nLeast squares means are from an analysis of covariance (ANCOVA) model with treatment and geographic region as fixed effects, and baseline HbA1c as a covariate.", "timeFrame": "Baseline and Weeks 4, 8, 12, 16, and 20."}, {"measure": "Change From Baseline in Fasting Plasma Glucose Over Time", "description": "The change from Baseline in fasting plasma glucose was assessed at Weeks 1, 2, 4, 8, 12, 16, 20 and 26. Least Squares Means were from an ANCOVA model with treatment and geographic region as fixed effects, and baseline fasting plasma glucose as a covariate.", "timeFrame": "Baseline and Weeks 1, 2, 4, 8, 12, 16, 20 and 26."}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Has historical diagnosis of Type 2 Diabetes Mellitus.\n* Has been treated with diet and exercise for at least 2 months prior to Screening, and has a Glycosylated Hemoglobin concentration between 7.5% and 10.0%, inclusive at Screening.\n* Has received less than 7 days of any antidiabetic medication within 2 months prior to Screening.\n* Body mass index greater than or equal to 23 kg/m\\^2 and less than or equal to 45 kg/m\\^2 (except for Asian or Asian-descendant subjects for whom the range is between 20 and 35 kg/ m\\^2, inclusive).\n* Fasting C-peptide concentration greater than or equal to 0.8 ng/mL.\n* Regularly using other, non-excluded, medications must be on a stable dose for at least the 4 weeks prior to Screening.\n* Females of childbearing potential and males who are sexually active agree to routinely use adequate contraception from Screening throughout the duration of the study.\n* Able and willing to monitor their own blood glucose concentrations with a home glucose monitor and complete patient diaries.\n\nExclusion Criteria:\n\n* Hemoglobin less than 12 g/dL for males and less than 10 g/dL for females at Screening Visit.\n* Has a history of any hemoglobinopathy that may affect determination of Glycosylated Hemoglobin.\n* Has a history of laser treatment for proliferative diabetic retinopathy within the 6 months prior to Screening.\n* Has a history of treatment for diabetic gastric paresis, gastric banding, or gastric bypass surgery.\n* Has a history of diabetic ketoacidosis or hyperosmolar non-ketotic coma.\n* Has systolic blood pressure greater than or equal to 150 mmHg and /or diastolic pressure greater than or equal to 90 mmHg at Screening visit.\n* Has New York Heart Association Class III to IV heart failure.\n* Has a history of coronary angioplasty, coronary stent placement, coronary bypass surgery, or myocardial infarction within the 90 days prior to Screening.\n* Has Alanine aminotransferase greater than 3 times the upper limit of normal at Screening.\n* Has a history of alcohol or substance abuse with the 2 years prior to Screening.\n* Serum creatinine greater than or equal to 1.5 mg/dL for males and greater than or equal to 1.4 mg/dL for females.\n* Has history of cancer, other than squamous cell or basal cell carcinoma of the skin that has not been in full remission for at least 5 years prior to Screening.\n* Has a history of infection with human immunodeficiency virus, hepatitis B virus or hepatitis C virus.\n* Has any major illness or debility that in the investigator's opinion prohibits the subject from completing the study.\n* Has received any investigational drug within the 90 days prior to Screening.\n* Has a history of hypersensitivity or allergy to alogliptin, other DPP-4 inhibitors, metformin or related compounds.\n* Has used oral or systematically injected glucocorticoids or weight loss drugs prior to 2 months to screening.", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "maximumAge": "80 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Vice President, Clinical Science", "affiliation": "Takeda", "role": "STUDY_DIRECTOR"}], "locations": [{"city": "Dothan", "state": "Alabama", "country": "United States", "geoPoint": {"lat": 31.22323, "lon": -85.39049}}, {"city": "Muscle Shoals", "state": "Alabama", "country": "United States", "geoPoint": {"lat": 34.74481, "lon": -87.66753}}, {"city": "Pell City", "state": "Alabama", "country": "United States", "geoPoint": {"lat": 33.58621, "lon": -86.28609}}, {"city": "Chandler", "state": "Arizona", "country": "United States", "geoPoint": {"lat": 33.30616, "lon": -111.84125}}, {"city": "Mesa", "state": "Arizona", "country": "United States", "geoPoint": {"lat": 33.42227, "lon": -111.82264}}, {"city": "Phoenix", "state": "Arizona", "country": "United States", "geoPoint": {"lat": 33.44838, "lon": -112.07404}}, {"city": "Sierra Vista", "state": "Arizona", "country": "United States", "geoPoint": {"lat": 31.55454, "lon": -110.30369}}, {"city": "Tempe", "state": "Arizona", "country": "United States", "geoPoint": {"lat": 33.41477, "lon": -111.90931}}, {"city": "Little Rock", "state": "Arkansas", "country": "United States", "geoPoint": {"lat": 34.74648, "lon": -92.28959}}, {"city": "Searcy", "state": "Arkansas", "country": "United States", "geoPoint": {"lat": 35.25064, "lon": -91.73625}}, {"city": "Tempe", "state": "Arkansas", "country": "United States"}, {"city": "Anaheim", "state": "California", "country": "United States", "geoPoint": {"lat": 33.83529, "lon": -117.9145}}, {"city": "Buena Park", "state": "California", "country": "United States", "geoPoint": {"lat": 33.86751, "lon": -117.99812}}, {"city": "Cathedral City", "state": "California", "country": "United States", "geoPoint": {"lat": 33.77974, "lon": -116.46529}}, {"city": "National City", "state": "California", "country": "United States", "geoPoint": {"lat": 32.67811, "lon": -117.0992}}, {"city": "Pismo Beach", "state": "California", "country": "United States", "geoPoint": {"lat": 35.14275, "lon": -120.64128}}, {"city": "Roseville", "state": "California", "country": "United States", "geoPoint": {"lat": 38.75212, "lon": -121.28801}}, {"city": "Santa Ana", "state": "California", "country": "United States", "geoPoint": {"lat": 33.74557, "lon": -117.86783}}, {"city": "Colorado Springs", "state": "Colorado", "country": "United States", "geoPoint": {"lat": 38.83388, "lon": -104.82136}}, {"city": "Boca Raton", "state": "Florida", "country": "United States", "geoPoint": {"lat": 26.3669, "lon": -80.13033}}, {"city": "Bradenton", "state": "Florida", "country": "United States", "geoPoint": {"lat": 27.49893, "lon": -82.57482}}, {"city": "Cutler Bay", "state": "Florida", "country": "United States", "geoPoint": {"lat": 25.5783, "lon": -80.3377}}, {"city": "Hialeah", "state": "Florida", "country": "United States", "geoPoint": {"lat": 25.8576, "lon": -80.27811}}, {"city": "Lauderdale Lakes", "state": "Florida", "country": "United States", "geoPoint": {"lat": 26.16647, "lon": -80.20838}}, {"city": "Miami", "state": "Florida", "country": "United States", "geoPoint": {"lat": 25.77427, "lon": -80.19366}}, {"city": "Ocala", "state": "Florida", "country": "United States", "geoPoint": {"lat": 29.1872, "lon": -82.14009}}, {"city": "Opa Locka", "state": "Florida", "country": "United States", "geoPoint": {"lat": 25.90232, "lon": -80.25033}}, {"city": "Orlando", "state": "Florida", "country": "United States", "geoPoint": {"lat": 28.53834, "lon": -81.37924}}, {"city": "Panama City", "state": "Florida", "country": "United States", "geoPoint": {"lat": 30.15946, "lon": -85.65983}}, {"city": "Pembroke Pines", "state": "Florida", "country": "United States", "geoPoint": {"lat": 26.00315, "lon": -80.22394}}, {"city": "Atlanta", "state": "Georgia", "country": "United States", "geoPoint": {"lat": 33.749, "lon": -84.38798}}, {"city": "Blue Ridge", "state": "Georgia", "country": "United States", "geoPoint": {"lat": 34.86397, "lon": -84.32409}}, {"city": "Decatur", "state": "Georgia", "country": "United States", "geoPoint": {"lat": 33.77483, "lon": -84.29631}}, {"city": "Lawrenceville", "state": "Georgia", "country": "United States", "geoPoint": {"lat": 33.95621, "lon": -83.98796}}, {"city": "Hayden Lake", "state": "Idaho", "country": "United States", "geoPoint": {"lat": 47.75879, "lon": -116.75686}}, {"city": "Chicago", "state": "Illinois", "country": "United States", "geoPoint": {"lat": 41.85003, "lon": -87.65005}}, {"city": "Melrose Park", "state": "Illinois", "country": "United States", "geoPoint": {"lat": 41.90059, "lon": -87.85673}}, {"city": "La Porte", "state": "Indiana", "country": "United States", "geoPoint": {"lat": 41.60774, "lon": -86.71389}}, {"city": "Mishawaka", "state": "Indiana", "country": "United States", "geoPoint": {"lat": 41.66199, "lon": -86.15862}}, {"city": "Council Bluffs", "state": "Iowa", "country": "United States", "geoPoint": {"lat": 41.26194, "lon": -95.86083}}, {"city": "Dubuque", "state": "Iowa", "country": "United States", "geoPoint": {"lat": 42.50056, "lon": -90.66457}}, {"city": "Topeka", "state": "Kansas", "country": "United States", "geoPoint": {"lat": 39.04833, "lon": -95.67804}}, {"city": "Lexington", "state": "Kentucky", "country": "United States", "geoPoint": {"lat": 37.98869, "lon": -84.47772}}, {"city": "Louisville", "state": "Kentucky", "country": "United States", "geoPoint": {"lat": 38.25424, "lon": -85.75941}}, {"city": "Marrero", "state": "Louisiana", "country": "United States", "geoPoint": {"lat": 29.89937, "lon": -90.10035}}, {"city": "Oxon Hill", "state": "Maryland", "country": "United States", "geoPoint": {"lat": 38.80345, "lon": -76.9897}}, {"city": "North Dartmouth", "state": "Massachusetts", "country": "United States", "geoPoint": {"lat": 41.63899, "lon": -70.97032}}, {"city": "Dearborn", "state": "Michigan", "country": "United States", "geoPoint": {"lat": 42.32226, "lon": -83.17631}}, {"city": "Flint", "state": "Michigan", "country": "United States", "geoPoint": {"lat": 43.01253, "lon": -83.68746}}, {"city": "Kalamazoo", "state": "Michigan", "country": "United States", "geoPoint": {"lat": 42.29171, "lon": -85.58723}}, {"city": "Picayune", "state": "Mississippi", "country": "United States", "geoPoint": {"lat": 30.52556, "lon": -89.67788}}, {"city": "St. Louis", "state": "Missouri", "country": "United States", "geoPoint": {"lat": 38.62727, "lon": -90.19789}}, {"city": "Omaha", "state": "Nebraska", "country": "United States", "geoPoint": {"lat": 41.25626, "lon": -95.94043}}, {"city": "Henderson", "state": "Nevada", "country": "United States", "geoPoint": {"lat": 36.0397, "lon": -114.98194}}, {"city": "Las Vegas", "state": "Nevada", "country": "United States", "geoPoint": {"lat": 36.17497, "lon": -115.13722}}, {"city": "Brick", "state": "New Jersey", "country": "United States", "geoPoint": {"lat": 40.05928, "lon": -74.13708}}, {"city": "Elizabeth", "state": "New Jersey", "country": "United States", "geoPoint": {"lat": 40.66399, "lon": -74.2107}}, {"city": "North Massapequa", "state": "New York", "country": "United States", "geoPoint": {"lat": 40.70093, "lon": -73.46207}}, {"city": "Asheville", "state": "North Carolina", "country": "United States", "geoPoint": {"lat": 35.60095, "lon": -82.55402}}, {"city": "Charlotte", "state": "North Carolina", "country": "United States", "geoPoint": {"lat": 35.22709, "lon": -80.84313}}, {"city": "Greensboro", "state": "North Carolina", "country": "United States", "geoPoint": {"lat": 36.07264, "lon": -79.79198}}, {"city": "Mooresville", "state": "North Carolina", "country": "United States", "geoPoint": {"lat": 35.58486, "lon": -80.81007}}, {"city": "Fargo", "state": "North Dakota", "country": "United States", "geoPoint": {"lat": 46.87719, "lon": -96.7898}}, {"city": "Cincinnati", "state": "Ohio", "country": "United States", "geoPoint": {"lat": 39.12713, "lon": -84.51435}}, {"city": "Cleveland", "state": "Ohio", "country": "United States", "geoPoint": {"lat": 41.4995, "lon": -81.69541}}, {"city": "Gallipolis", "state": "Ohio", "country": "United States", "geoPoint": {"lat": 38.8098, "lon": -82.20237}}, {"city": "Mason", "state": "Ohio", "country": "United States", "geoPoint": {"lat": 39.36006, "lon": -84.30994}}, {"city": "Maumee", "state": "Ohio", "country": "United States", "geoPoint": {"lat": 41.56283, "lon": -83.65382}}, {"city": "Norman", "state": "Oklahoma", "country": "United States", "geoPoint": {"lat": 35.22257, "lon": -97.43948}}, {"city": "Oklahoma City", "state": "Oklahoma", "country": "United States", "geoPoint": {"lat": 35.46756, "lon": -97.51643}}, {"city": "Tulsa", "state": "Oklahoma", "country": "United States", "geoPoint": {"lat": 36.15398, "lon": -95.99277}}, {"city": "Altoona", "state": "Pennsylvania", "country": "United States", "geoPoint": {"lat": 40.51868, "lon": -78.39474}}, {"city": "Bensalem", "state": "Pennsylvania", "country": "United States", "geoPoint": {"lat": 40.10455, "lon": -74.95128}}, {"city": "Downingtown", "state": "Pennsylvania", "country": "United States", "geoPoint": {"lat": 40.0065, "lon": -75.70327}}, {"city": "Fleetwood", "state": "Pennsylvania", "country": "United States", "geoPoint": {"lat": 40.45398, "lon": -75.81798}}, {"city": "Perkasie", "state": "Pennsylvania", "country": "United States", "geoPoint": {"lat": 40.37205, "lon": -75.29268}}, {"city": "Shippensburg", "state": "Pennsylvania", "country": "United States", "geoPoint": {"lat": 40.05065, "lon": -77.52026}}, {"city": "Tipton", "state": "Pennsylvania", "country": "United States", "geoPoint": {"lat": 40.6359, "lon": -78.29585}}, {"city": "Uniontown", "state": "Pennsylvania", "country": "United States", "geoPoint": {"lat": 39.90008, "lon": -79.71643}}, {"city": "Columbia", "state": "South Carolina", "country": "United States", "geoPoint": {"lat": 34.00071, "lon": -81.03481}}, {"city": "Greenville", "state": "South Carolina", "country": "United States", "geoPoint": {"lat": 34.85262, "lon": -82.39401}}, {"city": "Murrells Inlet", "state": "South Carolina", "country": "United States", "geoPoint": {"lat": 33.551, "lon": -79.04143}}, {"city": "North Myrtle Beach", "state": "South Carolina", "country": "United States", "geoPoint": {"lat": 33.81601, "lon": -78.68002}}, {"city": "Taylors", "state": "South Carolina", "country": "United States", "geoPoint": {"lat": 34.92039, "lon": -82.29623}}, {"city": "Brentwood", "state": "Tennessee", "country": "United States", "geoPoint": {"lat": 36.03312, "lon": -86.78278}}, {"city": "Bristol", "state": "Tennessee", "country": "United States", "geoPoint": {"lat": 36.59511, "lon": -82.18874}}, {"city": "Crossville", "state": "Tennessee", "country": "United States", "geoPoint": {"lat": 35.94896, "lon": -85.0269}}, {"city": "Johnson City", "state": "Tennessee", "country": "United States", "geoPoint": {"lat": 36.31344, "lon": -82.35347}}, {"city": "McKenzie", "state": "Tennessee", "country": "United States", "geoPoint": {"lat": 36.13256, "lon": -88.51866}}, {"city": "Spring Hill", "state": "Tennessee", "country": "United States", "geoPoint": {"lat": 35.75118, "lon": -86.93}}, {"city": "Carrollton", "state": "Texas", "country": "United States", "geoPoint": {"lat": 32.95373, "lon": -96.89028}}, {"city": "Dallas", "state": "Texas", "country": "United States", "geoPoint": {"lat": 32.78306, "lon": -96.80667}}, {"city": "Deer Park", "state": "Texas", "country": "United States", "geoPoint": {"lat": 29.70523, "lon": -95.12382}}, {"city": "El Paso", "state": "Texas", "country": "United States", "geoPoint": {"lat": 31.75872, "lon": -106.48693}}, {"city": "Houston", "state": "Texas", "country": "United States", "geoPoint": {"lat": 29.76328, "lon": -95.36327}}, {"city": "Hurst", "state": "Texas", "country": "United States", "geoPoint": {"lat": 32.82346, "lon": -97.17057}}, {"city": "Katy", "state": "Texas", "country": "United States", "geoPoint": {"lat": 29.78579, "lon": -95.8244}}, {"city": "Odessa", "state": "Texas", "country": "United States", "geoPoint": {"lat": 31.84568, "lon": -102.36764}}, {"city": "San Antonio", "state": "Texas", "country": "United States", "geoPoint": {"lat": 29.42412, "lon": -98.49363}}, {"city": "Schertz", "state": "Texas", "country": "United States", "geoPoint": {"lat": 29.55217, "lon": -98.26973}}, {"city": "Spring", "state": "Texas", "country": "United States", "geoPoint": {"lat": 30.07994, "lon": -95.41716}}, {"city": "Sugarland", "state": "Texas", "country": "United States", "geoPoint": {"lat": 29.61968, "lon": -95.63495}}, {"city": "Temple", "state": "Texas", "country": "United States", "geoPoint": {"lat": 31.09823, "lon": -97.34278}}, {"city": "Bountiful", "state": "Utah", "country": "United States", "geoPoint": {"lat": 40.88939, "lon": -111.88077}}, {"city": "Ogden", "state": "Utah", "country": "United States", "geoPoint": {"lat": 41.223, "lon": -111.97383}}, {"city": "Salt Lake City", "state": "Utah", "country": "United States", "geoPoint": {"lat": 40.76078, "lon": -111.89105}}, {"city": "South Burlington", "state": "Vermont", "country": "United States", "geoPoint": {"lat": 44.46699, "lon": -73.17096}}, {"city": "Petersburg", "state": "Virginia", "country": "United States", "geoPoint": {"lat": 37.22793, "lon": -77.40193}}, {"city": "Milwaukee", "state": "Wisconsin", "country": "United States", "geoPoint": {"lat": 43.0389, "lon": -87.90647}}, {"city": "Hradec Kralove", "country": "Czech Republic", "geoPoint": {"lat": 50.20923, "lon": 15.83277}}, {"city": "Olomouc", "country": "Czech Republic", "geoPoint": {"lat": 49.59552, "lon": 17.25175}}, {"city": "Ostrava", "country": "Czech Republic", "geoPoint": {"lat": 49.83465, "lon": 18.28204}}, {"city": "Praha 10", "country": "Czech Republic", "geoPoint": {"lat": 50.08804, "lon": 14.42076}}, {"city": "Zlin", "country": "Czech Republic", "geoPoint": {"lat": 49.22645, "lon": 17.67065}}, {"city": "Znojmo", "country": "Czech Republic", "geoPoint": {"lat": 48.8555, "lon": 16.0488}}, {"city": "Budaors", "country": "Hungary", "geoPoint": {"lat": 47.46181, "lon": 18.95845}}, {"city": "Debrecen", "country": "Hungary", "geoPoint": {"lat": 47.53333, "lon": 21.63333}}, {"city": "Gyongyos", "country": "Hungary", "geoPoint": {"lat": 47.78257, "lon": 19.928}}, {"city": "Gyor", "country": "Hungary", "geoPoint": {"lat": 47.68333, "lon": 17.63512}}, {"city": "Gyula", "country": "Hungary", "geoPoint": {"lat": 46.65, "lon": 21.28333}}, {"city": "Komarom", "country": "Hungary", "geoPoint": {"lat": 47.74318, "lon": 18.11913}}, {"city": "Szolnok", "country": "Hungary", "geoPoint": {"lat": 47.18333, "lon": 20.2}}, {"city": "Zalaegerszeg", "country": "Hungary", "geoPoint": {"lat": 46.84, "lon": 16.84389}}, {"city": "Haifa", "country": "Israel", "geoPoint": {"lat": 32.81841, "lon": 34.9885}}, {"city": "Holon", "country": "Israel", "geoPoint": {"lat": 32.01034, "lon": 34.77918}}, {"city": "Kfar Saba", "country": "Israel", "geoPoint": {"lat": 32.175, "lon": 34.90694}}, {"city": "Nahariya", "country": "Israel", "geoPoint": {"lat": 33.00892, "lon": 35.09814}}, {"city": "Safed", "country": "Israel", "geoPoint": {"lat": 32.96465, "lon": 35.496}}, {"city": "Kaunas", "country": "Lithuania", "geoPoint": {"lat": 54.90272, "lon": 23.90961}}, {"city": "Kedainiai", "country": "Lithuania", "geoPoint": {"lat": 55.28782, "lon": 23.97276}}, {"city": "Klaipeda", "country": "Lithuania", "geoPoint": {"lat": 55.70888, "lon": 21.14311}}, {"city": "Vilnius", "country": "Lithuania", "geoPoint": {"lat": 54.68916, "lon": 25.2798}}, {"city": "Acapulco, Guerrero", "country": "Mexico"}, {"city": "Cuernavaca", "country": "Mexico", "geoPoint": {"lat": 18.9261, "lon": -99.23075}}, {"city": "Culiacan, Sinoloa", "country": "Mexico"}, {"city": "Distrito Federal", "country": "Mexico", "geoPoint": {"lat": 16.59, "lon": -93.02694}}, {"city": "Durango, Durango", "country": "Mexico"}, {"city": "Durango", "country": "Mexico", "geoPoint": {"lat": 24.02032, "lon": -104.65756}}, {"city": "Guadalajara", "country": "Mexico", "geoPoint": {"lat": 20.66682, "lon": -103.39182}}, {"city": "Mexico City, Mexico", "country": "Mexico"}, {"city": "Mexico City", "country": "Mexico", "geoPoint": {"lat": 19.42847, "lon": -99.12766}}, {"city": "Mexico, DF", "country": "Mexico", "geoPoint": {"lat": 19.42847, "lon": -99.12766}}, {"city": "Monclova, Coahuila", "country": "Mexico"}, {"city": "Monterrey, NL", "country": "Mexico"}, {"city": "Monterrey", "country": "Mexico", "geoPoint": {"lat": 25.67507, "lon": -100.31847}}, {"city": "Pachuca, Hidalgo", "country": "Mexico"}, {"city": "Pachuca", "country": "Mexico", "geoPoint": {"lat": 20.11697, "lon": -98.73329}}, {"city": "Saltillo", "country": "Mexico", "geoPoint": {"lat": 25.42321, "lon": -101.0053}}, {"city": "Tijuana, Baja California", "country": "Mexico"}, {"city": "Zapopan, Jalisco", "country": "Mexico", "geoPoint": {"lat": 20.72356, "lon": -103.38479}}, {"city": "Bialystok", "country": "Poland", "geoPoint": {"lat": 53.13333, "lon": 23.16433}}, {"city": "Bytom", "country": "Poland", "geoPoint": {"lat": 50.34802, "lon": 18.93282}}, {"city": "Gniewkowo", "country": "Poland", "geoPoint": {"lat": 52.89461, "lon": 18.40785}}, {"city": "Grodzisk Mazowiecki", "country": "Poland", "geoPoint": {"lat": 52.10387, "lon": 20.6337}}, {"city": "Kamieniec Zabkowicki", "country": "Poland", "geoPoint": {"lat": 50.52541, "lon": 16.87921}}, {"city": "Leczyca", "country": "Poland", "geoPoint": {"lat": 52.05959, "lon": 19.19972}}, {"city": "Warszawa", "country": "Poland", "geoPoint": {"lat": 52.22977, "lon": 21.01178}}, {"city": "Wroclaw", "country": "Poland", "geoPoint": {"lat": 51.1, "lon": 17.03333}}, {"city": "Caguas", "country": "Puerto Rico", "geoPoint": {"lat": 18.23412, "lon": -66.0485}}, {"city": "Cidra", "country": "Puerto Rico", "geoPoint": {"lat": 18.17579, "lon": -66.16128}}, {"city": "Ponce", "country": "Puerto Rico", "geoPoint": {"lat": 18.01108, "lon": -66.61406}}, {"city": "Salinas", "country": "Puerto Rico", "geoPoint": {"lat": 17.97747, "lon": -66.29795}}, {"city": "San Juan", "country": "Puerto Rico", "geoPoint": {"lat": 18.46633, "lon": -66.10572}}, {"city": "Santurce", "country": "Puerto Rico", "geoPoint": {"lat": 18.19523, "lon": -67.14018}}, {"city": "Trujilo Alto", "country": "Puerto Rico"}, {"city": "Bacau", "country": "Romania", "geoPoint": {"lat": 46.56718, "lon": 26.91384}}, {"city": "Baia Mare", "country": "Romania", "geoPoint": {"lat": 47.65529, "lon": 23.57381}}, {"city": "Bucharest", "country": "Romania", "geoPoint": {"lat": 44.43225, "lon": 26.10626}}, {"city": "Constanta", "country": "Romania", "geoPoint": {"lat": 44.18073, "lon": 28.63432}}, {"city": "Iasi", "country": "Romania", "geoPoint": {"lat": 47.16667, "lon": 27.6}}, {"city": "Ploiesti", "country": "Romania", "geoPoint": {"lat": 44.95, "lon": 26.01667}}, {"city": "Arkhangelsk", "country": "Russian Federation", "geoPoint": {"lat": 64.5401, "lon": 40.5433}}, {"city": "Irkutsk", "country": "Russian Federation", "geoPoint": {"lat": 52.29778, "lon": 104.29639}}, {"city": "Kemerovo", "country": "Russian Federation", "geoPoint": {"lat": 55.33333, "lon": 86.08333}}, {"city": "Moscow", "country": "Russian Federation", "geoPoint": {"lat": 55.75222, "lon": 37.61556}}, {"city": "Perm", "country": "Russian Federation", "geoPoint": {"lat": 58.01046, "lon": 56.25017}}, {"city": "St. Petersburg", "country": "Russian Federation", "geoPoint": {"lat": 59.93863, "lon": 30.31413}}, {"city": "Ufa", "country": "Russian Federation", "geoPoint": {"lat": 54.74306, "lon": 55.96779}}, {"city": "Banska Bystrica", "country": "Slovakia", "geoPoint": {"lat": 48.73946, "lon": 19.15349}}, {"city": "Kosice", "country": "Slovakia", "geoPoint": {"lat": 48.71395, "lon": 21.25808}}, {"city": "Lucenec", "country": "Slovakia", "geoPoint": {"lat": 48.33249, "lon": 19.66708}}, {"city": "Nitra", "country": "Slovakia", "geoPoint": {"lat": 48.30763, "lon": 18.08453}}, {"city": "Presov", "country": "Slovakia", "geoPoint": {"lat": 48.99839, "lon": 21.23393}}, {"city": "Prievidza", "country": "Slovakia", "geoPoint": {"lat": 48.77446, "lon": 18.6275}}, {"city": "Sahy", "country": "Slovakia", "geoPoint": {"lat": 48.07408, "lon": 18.94946}}, {"city": "Zilina", "country": "Slovakia", "geoPoint": {"lat": 49.22315, "lon": 18.73941}}, {"city": "Centurion", "state": "Gauteng", "country": "South Africa", "geoPoint": {"lat": -25.85891, "lon": 28.18577}}, {"city": "Johannesburg", "state": "Gauteng", "country": "South Africa", "geoPoint": {"lat": -26.20227, "lon": 28.04363}}, {"city": "Pretoria", "state": "Gauteng", "country": "South Africa", "geoPoint": {"lat": -25.74486, "lon": 28.18783}}, {"city": "Durban", "state": "Kwazulu-Natal", "country": "South Africa", "geoPoint": {"lat": -29.8579, "lon": 31.0292}}, {"city": "Cape Town", "state": "Western Cape", "country": "South Africa", "geoPoint": {"lat": -33.92584, "lon": 18.42322}}, {"city": "Pretoria", "country": "South Africa", "geoPoint": {"lat": -25.74486, "lon": 28.18783}}, {"city": "Dnipropetrovsk", "country": "Ukraine", "geoPoint": {"lat": 48.4593, "lon": 35.03864}}, {"city": "Donetsk", "country": "Ukraine", "geoPoint": {"lat": 48.023, "lon": 37.80224}}, {"city": "Ivano-Frankivsk", "country": "Ukraine", "geoPoint": {"lat": 48.9215, "lon": 24.70972}}, {"city": "Kharkiv", "country": "Ukraine", "geoPoint": {"lat": 49.98081, "lon": 36.25272}}, {"city": "Kyiv", "country": "Ukraine", "geoPoint": {"lat": 50.45466, "lon": 30.5238}}, {"city": "Lviv", "country": "Ukraine", "geoPoint": {"lat": 49.83826, "lon": 24.02324}}, {"city": "Odesa", "country": "Ukraine", "geoPoint": {"lat": 46.47747, "lon": 30.73262}}, {"city": "Vinnytsya", "country": "Ukraine", "geoPoint": {"lat": 49.23278, "lon": 28.48097}}, {"city": "Zaporizhzhya", "country": "Ukraine", "geoPoint": {"lat": 50.60727, "lon": 31.78792}}]}, "referencesModule": {"references": [{"pmid": "24400655", "type": "DERIVED", "citation": "Pratley RE, Fleck P, Wilson C. Efficacy and safety of initial combination therapy with alogliptin plus metformin versus either as monotherapy in drug-naive patients with type 2 diabetes: a randomized, double-blind, 6-month study. Diabetes Obes Metab. 2014 Jul;16(7):613-21. doi: 10.1111/dom.12258. Epub 2014 Feb 12."}]}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "Participants with a diagnosis of type 2 diabetes and glycemia inadequately controlled on diet and exercise alone were randomly assigned with equal probability to 1 of 7 treatment groups, including placebo, alogliptin alone, metformin alone or a combination of alogliptin and metformin.", "recruitmentDetails": "Participants took part in the study at 198 investigative sites worldwide from 16 November 2009 to 30 June 2011.", "groups": [{"id": "FG000", "title": "Placebo", "description": "Alogliptin placebo-matching tablets, orally, twice daily and Metformin placebo-matching capsules, orally, twice daily for up to 26 weeks."}, {"id": "FG001", "title": "Alogliptin 25 QD", "description": "Alogliptin 25 mg, tablets, orally, once daily (QD) and Metformin placebo-matching capsules, orally, twice daily for up to 26 weeks."}, {"id": "FG002", "title": "Alogliptin 12.5 BID", "description": "Alogliptin 12.5 mg, tablets, orally, twice daily (BID) and Metformin placebo-matching capsules, orally, twice daily for up to 26 weeks."}, {"id": "FG003", "title": "Metformin 500 BID", "description": "Alogliptin placebo-matching tablets, orally, twice daily and Metformin 500 mg capsules, orally, twice daily for up to 26 weeks."}, {"id": "FG004", "title": "Metformin 1000 BID", "description": "Alogliptin placebo-matching tablets, orally, twice daily and Metformin 1000 mg capsules, orally, twice daily for up to 26 weeks."}, {"id": "FG005", "title": "Alogliptin 12.5 BID + Metformin 500 BID", "description": "Alogliptin 12.5mg, tablets, orally, twice daily and Metformin 500 mg, capsules, orally, twice daily for up to 26 weeks."}, {"id": "FG006", "title": "Alogliptin 12.5 BID + Metformin 1000 BID", "description": "Alogliptin 12.5 mg, tablets, orally, twice daily and Metformin 1000 mg, capsules, orally, twice daily for up to 26 weeks."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "109"}, {"groupId": "FG001", "numSubjects": "112"}, {"groupId": "FG002", "numSubjects": "113"}, {"groupId": "FG003", "numSubjects": "114"}, {"groupId": "FG004", "numSubjects": "111"}, {"groupId": "FG005", "numSubjects": "111"}, {"groupId": "FG006", "numSubjects": "114"}]}, {"type": "Received Study Treatment", "achievements": [{"groupId": "FG000", "numSubjects": "106"}, {"groupId": "FG001", "numSubjects": "112"}, {"groupId": "FG002", "numSubjects": "110"}, {"groupId": "FG003", "numSubjects": "109"}, {"groupId": "FG004", "numSubjects": "111"}, {"groupId": "FG005", "numSubjects": "106"}, {"groupId": "FG006", "numSubjects": "114"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "comment": "The number of completed patients represents those who completed study drug.", "numSubjects": "74"}, {"groupId": "FG001", "numSubjects": "89"}, {"groupId": "FG002", "numSubjects": "71"}, {"groupId": "FG003", "numSubjects": "94"}, {"groupId": "FG004", "numSubjects": "95"}, {"groupId": "FG005", "numSubjects": "92"}, {"groupId": "FG006", "numSubjects": "94"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "35"}, {"groupId": "FG001", "numSubjects": "23"}, {"groupId": "FG002", "numSubjects": "42"}, {"groupId": "FG003", "numSubjects": "20"}, {"groupId": "FG004", "numSubjects": "16"}, {"groupId": "FG005", "numSubjects": "19"}, {"groupId": "FG006", "numSubjects": "20"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "4"}, {"groupId": "FG001", "numSubjects": "4"}, {"groupId": "FG002", "numSubjects": "7"}, {"groupId": "FG003", "numSubjects": "3"}, {"groupId": "FG004", "numSubjects": "2"}, {"groupId": "FG005", "numSubjects": "5"}, {"groupId": "FG006", "numSubjects": "11"}]}, {"type": "Major protocol deviation", "reasons": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "3"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "0"}, {"groupId": "FG006", "numSubjects": "0"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "4"}, {"groupId": "FG001", "numSubjects": "8"}, {"groupId": "FG002", "numSubjects": "7"}, {"groupId": "FG003", "numSubjects": "2"}, {"groupId": "FG004", "numSubjects": "5"}, {"groupId": "FG005", "numSubjects": "2"}, {"groupId": "FG006", "numSubjects": "2"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "13"}, {"groupId": "FG001", "numSubjects": "8"}, {"groupId": "FG002", "numSubjects": "16"}, {"groupId": "FG003", "numSubjects": "10"}, {"groupId": "FG004", "numSubjects": "6"}, {"groupId": "FG005", "numSubjects": "8"}, {"groupId": "FG006", "numSubjects": "5"}]}, {"type": "Pregnancy", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "2"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "1"}, {"groupId": "FG006", "numSubjects": "0"}]}, {"type": "Lack of Efficacy", "reasons": [{"groupId": "FG000", "numSubjects": "9"}, {"groupId": "FG001", "numSubjects": "3"}, {"groupId": "FG002", "numSubjects": "6"}, {"groupId": "FG003", "numSubjects": "2"}, {"groupId": "FG004", "numSubjects": "1"}, {"groupId": "FG005", "numSubjects": "2"}, {"groupId": "FG006", "numSubjects": "1"}]}, {"type": "Physician Decision", "reasons": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "2"}, {"groupId": "FG003", "numSubjects": "1"}, {"groupId": "FG004", "numSubjects": "1"}, {"groupId": "FG005", "numSubjects": "1"}, {"groupId": "FG006", "numSubjects": "1"}]}, {"type": "Other", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "1"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "1"}, {"groupId": "FG005", "numSubjects": "0"}, {"groupId": "FG006", "numSubjects": "0"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Placebo", "description": "Alogliptin placebo-matching tablets, orally, twice daily and Metformin placebo-matching capsules, orally, twice daily for up to 26 weeks."}, {"id": "BG001", "title": "Alogliptin 25 QD", "description": "Alogliptin 25 mg, tablets, orally, once daily (QD) and Metformin placebo-matching capsules, orally, twice daily for up to 26 weeks."}, {"id": "BG002", "title": "Alogliptin 12.5 BID", "description": "Alogliptin 12.5 mg, tablets, orally, twice daily (BID) and Metformin placebo-matching capsules, orally, twice daily for up to 26 weeks."}, {"id": "BG003", "title": "Metformin 500 BID", "description": "Alogliptin placebo-matching tablets, orally, twice daily and Metformin 500 mg capsules, orally, twice daily for up to 26 weeks."}, {"id": "BG004", "title": "Metformin 1000 BID", "description": "Alogliptin placebo-matching tablets, orally, twice daily and Metformin 1000 mg capsules, orally, twice daily for up to 26 weeks."}, {"id": "BG005", "title": "Alogliptin 12.5 BID + Metformin 500 BID", "description": "Alogliptin 12.5mg, tablets, orally, twice daily and Metformin 500 mg, capsules, orally, twice daily for up to 26 weeks."}, {"id": "BG006", "title": "Alogliptin 12.5 BID + Metformin 1000 BID", "description": "Alogliptin 12.5 mg, tablets, orally, twice daily and Metformin 1000 mg, capsules, orally, twice daily for up to 26 weeks."}, {"id": "BG007", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "109"}, {"groupId": "BG001", "value": "112"}, {"groupId": "BG002", "value": "113"}, {"groupId": "BG003", "value": "114"}, {"groupId": "BG004", "value": "111"}, {"groupId": "BG005", "value": "111"}, {"groupId": "BG006", "value": "114"}, {"groupId": "BG007", "value": "784"}]}], "measures": [{"title": "Age Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "53.1", "spread": "9.60"}, {"groupId": "BG001", "value": "52.6", "spread": "9.38"}, {"groupId": "BG002", "value": "53.7", "spread": "9.70"}, {"groupId": "BG003", "value": "54.6", "spread": "10.20"}, {"groupId": "BG004", "value": "52.6", "spread": "11.30"}, {"groupId": "BG005", "value": "53.7", "spread": "11.59"}, {"groupId": "BG006", "value": "54.6", "spread": "10.42"}, {"groupId": "BG007", "value": "53.5", "spread": "10.33"}]}]}]}, {"title": "Age, Customized", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "<65 years", "categories": [{"measurements": [{"groupId": "BG000", "value": "100"}, {"groupId": "BG001", "value": "103"}, {"groupId": "BG002", "value": "96"}, {"groupId": "BG003", "value": "95"}, {"groupId": "BG004", "value": "94"}, {"groupId": "BG005", "value": "91"}, {"groupId": "BG006", "value": "96"}, {"groupId": "BG007", "value": "675"}]}]}, {"title": "\u226565 years", "categories": [{"measurements": [{"groupId": "BG000", "value": "9"}, {"groupId": "BG001", "value": "9"}, {"groupId": "BG002", "value": "17"}, {"groupId": "BG003", "value": "19"}, {"groupId": "BG004", "value": "17"}, {"groupId": "BG005", "value": "20"}, {"groupId": "BG006", "value": "18"}, {"groupId": "BG007", "value": "109"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "54"}, {"groupId": "BG001", "value": "64"}, {"groupId": "BG002", "value": "50"}, {"groupId": "BG003", "value": "67"}, {"groupId": "BG004", "value": "60"}, {"groupId": "BG005", "value": "63"}, {"groupId": "BG006", "value": "52"}, {"groupId": "BG007", "value": "410"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "55"}, {"groupId": "BG001", "value": "48"}, {"groupId": "BG002", "value": "63"}, {"groupId": "BG003", "value": "47"}, {"groupId": "BG004", "value": "51"}, {"groupId": "BG005", "value": "48"}, {"groupId": "BG006", "value": "62"}, {"groupId": "BG007", "value": "374"}]}]}]}, {"title": "Race/Ethnicity, Customized", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "Hispanic or Latino", "categories": [{"measurements": [{"groupId": "BG000", "value": "45"}, {"groupId": "BG001", "value": "43"}, {"groupId": "BG002", "value": "43"}, {"groupId": "BG003", "value": "45"}, {"groupId": "BG004", "value": "42"}, {"groupId": "BG005", "value": "45"}, {"groupId": "BG006", "value": "39"}, {"groupId": "BG007", "value": "302"}]}]}, {"title": "Not Hispanic or Latino", "categories": [{"measurements": [{"groupId": "BG000", "value": "64"}, {"groupId": "BG001", "value": "69"}, {"groupId": "BG002", "value": "70"}, {"groupId": "BG003", "value": "69"}, {"groupId": "BG004", "value": "69"}, {"groupId": "BG005", "value": "66"}, {"groupId": "BG006", "value": "75"}, {"groupId": "BG007", "value": "482"}]}]}]}, {"title": "Race/Ethnicity, Customized", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "American Indian or Alaska Native", "categories": [{"measurements": [{"groupId": "BG000", "value": "5"}, {"groupId": "BG001", "value": "8"}, {"groupId": "BG002", "value": "5"}, {"groupId": "BG003", "value": "3"}, {"groupId": "BG004", "value": "6"}, {"groupId": "BG005", "value": "9"}, {"groupId": "BG006", "value": "5"}, {"groupId": "BG007", "value": "41"}]}]}, {"title": "Asian", "categories": [{"measurements": [{"groupId": "BG000", "value": "20"}, {"groupId": "BG001", "value": "17"}, {"groupId": "BG002", "value": "21"}, {"groupId": "BG003", "value": "19"}, {"groupId": "BG004", "value": "20"}, {"groupId": "BG005", "value": "20"}, {"groupId": "BG006", "value": "26"}, {"groupId": "BG007", "value": "143"}]}]}, {"title": "Native Hawaiian or Other Pacific Islander", "categories": [{"measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "1"}, {"groupId": "BG003", "value": "0"}, {"groupId": "BG004", "value": "0"}, {"groupId": "BG005", "value": "0"}, {"groupId": "BG006", "value": "0"}, {"groupId": "BG007", "value": "1"}]}]}, {"title": "Black or African American", "categories": [{"measurements": [{"groupId": "BG000", "value": "8"}, {"groupId": "BG001", "value": "3"}, {"groupId": "BG002", "value": "3"}, {"groupId": "BG003", "value": "6"}, {"groupId": "BG004", "value": "6"}, {"groupId": "BG005", "value": "6"}, {"groupId": "BG006", "value": "5"}, {"groupId": "BG007", "value": "37"}]}]}, {"title": "White", "categories": [{"measurements": [{"groupId": "BG000", "value": "76"}, {"groupId": "BG001", "value": "84"}, {"groupId": "BG002", "value": "83"}, {"groupId": "BG003", "value": "85"}, {"groupId": "BG004", "value": "79"}, {"groupId": "BG005", "value": "76"}, {"groupId": "BG006", "value": "78"}, {"groupId": "BG007", "value": "561"}]}]}, {"title": "Multiracial", "categories": [{"measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "1"}, {"groupId": "BG004", "value": "0"}, {"groupId": "BG005", "value": "0"}, {"groupId": "BG006", "value": "0"}, {"groupId": "BG007", "value": "1"}]}]}]}, {"title": "Body Mass Index (BMI)", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "kg/m^2", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "31.15", "spread": "5.269"}, {"groupId": "BG001", "value": "30.81", "spread": "5.219"}, {"groupId": "BG002", "value": "30.36", "spread": "5.159"}, {"groupId": "BG003", "value": "30.19", "spread": "4.842"}, {"groupId": "BG004", "value": "30.51", "spread": "5.043"}, {"groupId": "BG005", "value": "30.92", "spread": "5.353"}, {"groupId": "BG006", "value": "31.04", "spread": "5.375"}, {"groupId": "BG007", "value": "30.71", "spread": "5.173"}]}]}]}, {"title": "Diabetes Duration", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "4.25", "spread": "4.778"}, {"groupId": "BG001", "value": "3.65", "spread": "4.119"}, {"groupId": "BG002", "value": "3.97", "spread": "4.800"}, {"groupId": "BG003", "value": "3.78", "spread": "3.904"}, {"groupId": "BG004", "value": "4.08", "spread": "4.587"}, {"groupId": "BG005", "value": "4.13", "spread": "4.777"}, {"groupId": "BG006", "value": "4.22", "spread": "4.972"}, {"groupId": "BG007", "value": "4.01", "spread": "4.563"}]}]}]}, {"title": "Baseline HbA1c", "description": "The count for baseline HbA1c category is based on HbA1c value used in randomization for stratification.", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "\u22648.5%", "categories": [{"measurements": [{"groupId": "BG000", "value": "65"}, {"groupId": "BG001", "value": "67"}, {"groupId": "BG002", "value": "67"}, {"groupId": "BG003", "value": "67"}, {"groupId": "BG004", "value": "66"}, {"groupId": "BG005", "value": "66"}, {"groupId": "BG006", "value": "67"}, {"groupId": "BG007", "value": "465"}]}]}, {"title": ">8.5%", "categories": [{"measurements": [{"groupId": "BG000", "value": "44"}, {"groupId": "BG001", "value": "45"}, {"groupId": "BG002", "value": "46"}, {"groupId": "BG003", "value": "47"}, {"groupId": "BG004", "value": "45"}, {"groupId": "BG005", "value": "45"}, {"groupId": "BG006", "value": "47"}, {"groupId": "BG007", "value": "319"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 26", "description": "The change from Baseline to Week 26 in HbA1c (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound).", "populationDescription": "Full analysis set (patients who took at least 1 dose of study medication) where baseline and at least 1 postbaseline assessment were available. Analysis includes only data collected on or after baseline and within 7 days after last dose of study medication or hyperglycemic rescue, whichever came first. Last observation carried forward was utilized.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "percentage glycosylated hemoglobin", "timeFrame": "Baseline and Week 26.", "groups": [{"id": "OG000", "title": "Placebo", "description": "Alogliptin placebo-matching tablets, orally, twice daily and Metformin placebo-matching capsules, orally, twice daily for up to 26 weeks."}, {"id": "OG001", "title": "Alogliptin 25 QD", "description": "Alogliptin 25 mg, tablets, orally, once daily (QD) and Metformin placebo-matching capsules, orally, twice daily for up to 26 weeks."}, {"id": "OG002", "title": "Alogliptin 12.5 BID", "description": "Alogliptin 12.5 mg, tablets, orally, twice daily (BID) and Metformin placebo-matching capsules, orally, twice daily for up to 26 weeks."}, {"id": "OG003", "title": "Metformin 500 BID", "description": "Alogliptin placebo-matching tablets, orally, twice daily and Metformin 500 mg capsules, orally, twice daily for up to 26 weeks."}, {"id": "OG004", "title": "Metformin 1000 BID", "description": "Alogliptin placebo-matching tablets, orally, twice daily and Metformin 1000 mg capsules, orally, twice daily for up to 26 weeks."}, {"id": "OG005", "title": "Alogliptin 12.5 BID + Metformin 500 BID", "description": "Alogliptin 12.5mg, tablets, orally, twice daily and Metformin 500 mg, capsules, orally, twice daily for up to 26 weeks."}, {"id": "OG006", "title": "Alogliptin 12.5 BID + Metformin 1000 BID", "description": "Alogliptin 12.5 mg, tablets, orally, twice daily and Metformin 1000 mg, capsules, orally, twice daily for up to 26 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "102"}, {"groupId": "OG001", "value": "104"}, {"groupId": "OG002", "value": "104"}, {"groupId": "OG003", "value": "103"}, {"groupId": "OG004", "value": "108"}, {"groupId": "OG005", "value": "102"}, {"groupId": "OG006", "value": "111"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.15", "spread": "0.094"}, {"groupId": "OG001", "value": "-0.52", "spread": "0.094"}, {"groupId": "OG002", "value": "-0.56", "spread": "0.093"}, {"groupId": "OG003", "value": "-0.65", "spread": "0.094"}, {"groupId": "OG004", "value": "-1.11", "spread": "0.092"}, {"groupId": "OG005", "value": "-1.22", "spread": "0.094"}, {"groupId": "OG006", "value": "-1.55", "spread": "0.090"}]}]}], "analyses": [{"groupIds": ["OG002", "OG005"], "groupDescription": "The primary efficacy analysis consisted of 2 separate sets of comparisons between each BID combination of alogliptin and metformin (alogliptin/metformin 12.5/500 mg BID and 12.5/1000 mg BID) and its constituent doses of alogliptin and metformin. The null hypothesis was that the combination of alogliptin and metformin had no additional effect on glycemic control at Week 26 either when compared with the constituent dose of alogliptin or with the constituent dose of metformin.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "pValueComment": "For each set of comparisons in the primary analysis, the null hypothesis was rejected only if both comparisons between a combination and its constituent doses were statistically significant at the 2-sided 2.5% level.", "statisticalMethod": "ANCOVA", "statisticalComment": "ANCOVA model with treatment and geographic region as fixed effects and baseline HbA1c as a covariate.", "paramType": "LS mean difference", "paramValue": "-0.67", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.96", "ciUpperLimit": "-0.37"}, {"groupIds": ["OG003", "OG005"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "statisticalMethod": "ANCOVA", "statisticalComment": "ANCOVA model with treatment and geographic region as fixed effects and baseline HbA1c as a covariate", "paramType": "LS mean difference", "paramValue": "-0.57", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.87", "ciUpperLimit": "-0.27"}, {"groupIds": ["OG002", "OG006"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "statisticalMethod": "ANCOVA", "statisticalComment": "ANCOVA model with treatment and geographic region as fixed effects and baseline HbA1c as a covariate.", "paramType": "LS mean difference", "paramValue": "-1.00", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-1.29", "ciUpperLimit": "-0.71"}, {"groupIds": ["OG004", "OG006"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "statisticalMethod": "ANCOVA", "statisticalComment": "ANCOVA model with treatment and geographic region as fixed effects and baseline HbA1c as a covariate.", "paramType": "LS mean difference", "paramValue": "-0.44", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.73", "ciUpperLimit": "-0.16"}]}, {"type": "SECONDARY", "title": "Change From Baseline in HbA1c Over Time", "description": "The change from Baseline in HbA1c (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) was assessed at Weeks 4, 8, 12, 16 and 20.\n\nLeast squares means are from an analysis of covariance (ANCOVA) model with treatment and geographic region as fixed effects, and baseline HbA1c as a covariate.", "populationDescription": "The full analysis set where a baseline assessment and at least 1 valid postbaseline assessment were available. The analysis includes only data collected on or after baseline and within 7 days after the last dose of study medication or hyperglycemic rescue, whichever came first. Last observation carried forward was utilized.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "percentage glycosylated hemoglobin", "timeFrame": "Baseline and Weeks 4, 8, 12, 16, and 20.", "groups": [{"id": "OG000", "title": "Placebo", "description": "Alogliptin placebo-matching tablets, orally, twice daily and Metformin placebo-matching capsules, orally, twice daily for up to 26 weeks."}, {"id": "OG001", "title": "Alogliptin 25 QD", "description": "Alogliptin 25 mg, tablets, orally, once daily (QD) and Metformin placebo-matching capsules, orally, twice daily for up to 26 weeks."}, {"id": "OG002", "title": "Alogliptin 12.5 BID", "description": "Alogliptin 12.5 mg, tablets, orally, twice daily (BID) and Metformin placebo-matching capsules, orally, twice daily for up to 26 weeks."}, {"id": "OG003", "title": "Metformin 500 BID", "description": "Alogliptin placebo-matching tablets, orally, twice daily and Metformin 500 mg capsules, orally, twice daily for up to 26 weeks."}, {"id": "OG004", "title": "Metformin 1000 BID", "description": "Alogliptin placebo-matching tablets, orally, twice daily and Metformin 1000 mg capsules, orally, twice daily for up to 26 weeks."}, {"id": "OG005", "title": "Alogliptin 12.5 BID + Metformin 500 BID", "description": "Alogliptin 12.5mg, tablets, orally, twice daily and Metformin 500 mg, capsules, orally, twice daily for up to 26 weeks."}, {"id": "OG006", "title": "Alogliptin 12.5 BID + Metformin 1000 BID", "description": "Alogliptin 12.5 mg, tablets, orally, twice daily and Metformin 1000 mg, capsules, orally, twice daily for up to 26 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "106"}, {"groupId": "OG001", "value": "112"}, {"groupId": "OG002", "value": "110"}, {"groupId": "OG003", "value": "109"}, {"groupId": "OG004", "value": "111"}, {"groupId": "OG005", "value": "106"}, {"groupId": "OG006", "value": "114"}]}], "classes": [{"title": "Week 4 (n=95, 97, 89, 94, 102, 94, 101)", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.09", "spread": "0.058"}, {"groupId": "OG001", "value": "-0.34", "spread": "0.057"}, {"groupId": "OG002", "value": "-0.42", "spread": "0.060"}, {"groupId": "OG003", "value": "-0.37", "spread": "0.058"}, {"groupId": "OG004", "value": "-0.58", "spread": "0.056"}, {"groupId": "OG005", "value": "-0.70", "spread": "0.058"}, {"groupId": "OG006", "value": "-0.75", "spread": "0.056"}]}]}, {"title": "Week 8 (n=102, 104, 104, 103, 108, 102, 111)", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.08", "spread": "0.073"}, {"groupId": "OG001", "value": "-0.51", "spread": "0.073"}, {"groupId": "OG002", "value": "-0.58", "spread": "0.072"}, {"groupId": "OG003", "value": "-0.59", "spread": "0.073"}, {"groupId": "OG004", "value": "-0.86", "spread": "0.071"}, {"groupId": "OG005", "value": "-1.08", "spread": "0.073"}, {"groupId": "OG006", "value": "-1.17", "spread": "0.070"}]}]}, {"title": "Week 12 (n=102, 104, 104, 103, 108, 102, 111)", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.12", "spread": "0.081"}, {"groupId": "OG001", "value": "-0.53", "spread": "0.080"}, {"groupId": "OG002", "value": "-0.62", "spread": "0.080"}, {"groupId": "OG003", "value": "-0.68", "spread": "0.081"}, {"groupId": "OG004", "value": "-1.02", "spread": "0.079"}, {"groupId": "OG005", "value": "-1.22", "spread": "0.081"}, {"groupId": "OG006", "value": "-1.40", "spread": "0.078"}]}]}, {"title": "Week 16 (n=102, 104, 104, 103, 108, 102, 111)", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.13", "spread": "0.087"}, {"groupId": "OG001", "value": "-0.58", "spread": "0.087"}, {"groupId": "OG002", "value": "-0.63", "spread": "0.086"}, {"groupId": "OG003", "value": "-0.72", "spread": "0.087"}, {"groupId": "OG004", "value": "-1.09", "spread": "0.085"}, {"groupId": "OG005", "value": "-1.26", "spread": "0.087"}, {"groupId": "OG006", "value": "-1.50", "spread": "0.084"}]}]}, {"title": "Week 20 (n=102, 104, 104, 103, 108, 102, 111)", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.12", "spread": "0.092"}, {"groupId": "OG001", "value": "-0.57", "spread": "0.091"}, {"groupId": "OG002", "value": "-0.59", "spread": "0.091"}, {"groupId": "OG003", "value": "-0.68", "spread": "0.092"}, {"groupId": "OG004", "value": "-1.14", "spread": "0.089"}, {"groupId": "OG005", "value": "-1.25", "spread": "0.092"}, {"groupId": "OG006", "value": "-1.54", "spread": "0.088"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Fasting Plasma Glucose Over Time", "description": "The change from Baseline in fasting plasma glucose was assessed at Weeks 1, 2, 4, 8, 12, 16, 20 and 26. Least Squares Means were from an ANCOVA model with treatment and geographic region as fixed effects, and baseline fasting plasma glucose as a covariate.", "populationDescription": "Full analysis set where a baseline assessment and at least 1 valid postbaseline assessment were available. Includes only data collected on or after baseline and within 1 day after the last dose of study medication or hyperglycemic rescue, whichever came first. Last observation carried forward was utilized.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mg/dL", "timeFrame": "Baseline and Weeks 1, 2, 4, 8, 12, 16, 20 and 26.", "groups": [{"id": "OG000", "title": "Placebo", "description": "Alogliptin placebo-matching tablets, orally, twice daily and Metformin placebo-matching capsules, orally, twice daily for up to 26 weeks."}, {"id": "OG001", "title": "Alogliptin 25 QD", "description": "Alogliptin 25 mg, tablets, orally, once daily (QD) and Metformin placebo-matching capsules, orally, twice daily for up to 26 weeks."}, {"id": "OG002", "title": "Alogliptin 12.5 BID", "description": "Alogliptin 12.5 mg, tablets, orally, twice daily (BID) and Metformin placebo-matching capsules, orally, twice daily for up to 26 weeks."}, {"id": "OG003", "title": "Metformin 500 BID", "description": "Alogliptin placebo-matching tablets, orally, twice daily and Metformin 500 mg capsules, orally, twice daily for up to 26 weeks."}, {"id": "OG004", "title": "Metformin 1000 BID", "description": "Alogliptin placebo-matching tablets, orally, twice daily and Metformin 1000 mg capsules, orally, twice daily for up to 26 weeks."}, {"id": "OG005", "title": "Alogliptin 12.5 BID + Metformin 500 BID", "description": "Alogliptin 12.5mg, tablets, orally, twice daily and Metformin 500 mg, capsules, orally, twice daily for up to 26 weeks."}, {"id": "OG006", "title": "Alogliptin 12.5 BID + Metformin 1000 BID", "description": "Alogliptin 12.5 mg, tablets, orally, twice daily and Metformin 1000 mg, capsules, orally, twice daily for up to 26 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "106"}, {"groupId": "OG001", "value": "112"}, {"groupId": "OG002", "value": "110"}, {"groupId": "OG003", "value": "109"}, {"groupId": "OG004", "value": "111"}, {"groupId": "OG005", "value": "106"}, {"groupId": "OG006", "value": "114"}]}], "classes": [{"title": "Week 1 (n=102, 103, 94, 95, 104, 101, 109)", "categories": [{"measurements": [{"groupId": "OG000", "value": "5.7", "spread": "3.40"}, {"groupId": "OG001", "value": "-3.9", "spread": "3.38"}, {"groupId": "OG002", "value": "-11.9", "spread": "3.54"}, {"groupId": "OG003", "value": "-12.6", "spread": "3.52"}, {"groupId": "OG004", "value": "-23.1", "spread": "3.36"}, {"groupId": "OG005", "value": "-32.7", "spread": "3.41"}, {"groupId": "OG006", "value": "-36.3", "spread": "3.29"}]}]}, {"title": "Week 2 (n=105, 112, 105, 102, 108, 106, 111)", "categories": [{"measurements": [{"groupId": "OG000", "value": "4.6", "spread": "3.58"}, {"groupId": "OG001", "value": "-7.4", "spread": "3.46"}, {"groupId": "OG002", "value": "-11.6", "spread": "3.58"}, {"groupId": "OG003", "value": "-14.5", "spread": "3.63"}, {"groupId": "OG004", "value": "-22.2", "spread": "3.53"}, {"groupId": "OG005", "value": "-34.5", "spread": "3.56"}, {"groupId": "OG006", "value": "-43.6", "spread": "3.48"}]}]}, {"title": "Week 4 (n=105, 112, 106, 106, 110, 106, 111)", "categories": [{"measurements": [{"groupId": "OG000", "value": "7.2", "spread": "3.69"}, {"groupId": "OG001", "value": "-11.5", "spread": "3.57"}, {"groupId": "OG002", "value": "-16.6", "spread": "3.67"}, {"groupId": "OG003", "value": "-16.9", "spread": "3.67"}, {"groupId": "OG004", "value": "-29.0", "spread": "3.60"}, {"groupId": "OG005", "value": "-37.6", "spread": "3.67"}, {"groupId": "OG006", "value": "-44.1", "spread": "3.58"}]}]}, {"title": "Week 8 (n=105, 112, 106, 106, 110, 106, 112)", "categories": [{"measurements": [{"groupId": "OG000", "value": "7.1", "spread": "4.00"}, {"groupId": "OG001", "value": "-10.9", "spread": "3.87"}, {"groupId": "OG002", "value": "-12.1", "spread": "3.98"}, {"groupId": "OG003", "value": "-11.8", "spread": "3.98"}, {"groupId": "OG004", "value": "-30.7", "spread": "3.91"}, {"groupId": "OG005", "value": "-32.9", "spread": "3.98"}, {"groupId": "OG006", "value": "-43.8", "spread": "3.87"}]}]}, {"title": "Week 12 (n=105, 112, 106, 106, 110, 106, 112)", "categories": [{"measurements": [{"groupId": "OG000", "value": "11.6", "spread": "4.16"}, {"groupId": "OG001", "value": "-9.7", "spread": "4.03"}, {"groupId": "OG002", "value": "-14.7", "spread": "4.14"}, {"groupId": "OG003", "value": "-14.0", "spread": "4.14"}, {"groupId": "OG004", "value": "-30.7", "spread": "4.06"}, {"groupId": "OG005", "value": "-31.6", "spread": "4.14"}, {"groupId": "OG006", "value": "-44.7", "spread": "4.03"}]}]}, {"title": "Week 16 (n=105, 112, 106, 106, 110, 106, 112)", "categories": [{"measurements": [{"groupId": "OG000", "value": "10.1", "spread": "4.17"}, {"groupId": "OG001", "value": "-7.1", "spread": "4.04"}, {"groupId": "OG002", "value": "-14.7", "spread": "4.15"}, {"groupId": "OG003", "value": "-13.3", "spread": "4.15"}, {"groupId": "OG004", "value": "-33.5", "spread": "4.07"}, {"groupId": "OG005", "value": "-35.9", "spread": "4.15"}, {"groupId": "OG006", "value": "-47.7", "spread": "4.04"}]}]}, {"title": "Week 20 (n=105, 112, 106, 106, 110, 106, 112)", "categories": [{"measurements": [{"groupId": "OG000", "value": "8.7", "spread": "4.36"}, {"groupId": "OG001", "value": "-9.2", "spread": "4.22"}, {"groupId": "OG002", "value": "-12.3", "spread": "4.34"}, {"groupId": "OG003", "value": "-10.9", "spread": "4.34"}, {"groupId": "OG004", "value": "-35.1", "spread": "4.25"}, {"groupId": "OG005", "value": "-33.8", "spread": "4.34"}, {"groupId": "OG006", "value": "-44.6", "spread": "4.22"}]}]}, {"title": "Week 26 (n=105, 112, 106, 106, 110, 106, 112)", "categories": [{"measurements": [{"groupId": "OG000", "value": "12.4", "spread": "4.52"}, {"groupId": "OG001", "value": "-6.1", "spread": "4.37"}, {"groupId": "OG002", "value": "-9.7", "spread": "4.49"}, {"groupId": "OG003", "value": "-11.5", "spread": "4.49"}, {"groupId": "OG004", "value": "-31.9", "spread": "4.41"}, {"groupId": "OG005", "value": "-31.7", "spread": "4.49"}, {"groupId": "OG006", "value": "-45.9", "spread": "4.37"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "timeFrame": "Adverse events that occurred after the first dose of double-blind study medication and within 14 days after the last dose of double-blind study medication.", "description": "At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment.", "eventGroups": [{"id": "EG000", "title": "Placebo", "description": "Alogliptin placebo-matching tablets, orally, twice daily and Metformin placebo-matching capsules, orally, twice daily for up to 26 weeks.", "seriousNumAffected": 3, "seriousNumAtRisk": 106, "otherNumAffected": 50, "otherNumAtRisk": 106}, {"id": "EG001", "title": "Alogliptin 25 QD", "description": "Alogliptin 25 mg, tablets, orally, once daily (QD) and Metformin placebo-matching capsules, orally, twice daily for up to 26 weeks.", "seriousNumAffected": 1, "seriousNumAtRisk": 112, "otherNumAffected": 38, "otherNumAtRisk": 112}, {"id": "EG002", "title": "Alogliptin 12.5 BID", "description": "Alogliptin 12.5 mg, tablets, orally, twice daily (BID) and Metformin placebo-matching capsules, orally, twice daily for up to 26 weeks.", "seriousNumAffected": 4, "seriousNumAtRisk": 110, "otherNumAffected": 34, "otherNumAtRisk": 110}, {"id": "EG003", "title": "Metformin 500 BID", "description": "Alogliptin placebo-matching tablets, orally, twice daily and Metformin 500 mg capsules, orally, twice daily for up to 26 weeks.", "seriousNumAffected": 3, "seriousNumAtRisk": 109, "otherNumAffected": 44, "otherNumAtRisk": 109}, {"id": "EG004", "title": "Metformin 1000 BID", "description": "Alogliptin placebo-matching tablets, orally, twice daily and Metformin 1000 mg capsules, orally, twice daily for up to 26 weeks.", "seriousNumAffected": 2, "seriousNumAtRisk": 111, "otherNumAffected": 43, "otherNumAtRisk": 111}, {"id": "EG005", "title": "Alogliptin 12.5 BID + Metformin 500 BID", "description": "Alogliptin 12.5mg, tablets, orally, twice daily and Metformin 500 mg, capsules, orally, twice daily for up to 26 weeks.", "seriousNumAffected": 2, "seriousNumAtRisk": 106, "otherNumAffected": 40, "otherNumAtRisk": 106}, {"id": "EG006", "title": "Alogliptin 12.5 BID + Metformin 1000 BID", "description": "Alogliptin 12.5 mg, tablets, orally, twice daily and Metformin 1000 mg, capsules, orally, twice daily for up to 26 weeks.", "seriousNumAffected": 2, "seriousNumAtRisk": 114, "otherNumAffected": 37, "otherNumAtRisk": 114}], "seriousEvents": [{"term": "Angina pectoris", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA (13.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 106}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 112}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 110}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 109}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 106}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 114}]}, {"term": "Myocardial ischaemia", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA (13.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 106}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 112}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 110}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 109}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 106}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 114}]}, {"term": "Wandering pacemaker", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA (13.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 106}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 112}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 110}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 109}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 111}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 106}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 114}]}, {"term": "Gallbladder empyema", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (13.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 106}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 112}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 110}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 109}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 106}, {"groupId": "EG006", "numAffected": 1, "numAtRisk": 114}]}, {"term": "Pneumonia", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (13.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 106}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 112}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 110}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 109}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 106}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 114}]}, {"term": "Urinary tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (13.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 106}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 112}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 110}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 109}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 106}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 114}]}, {"term": "Cerebrovascular accident", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA (13.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 106}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 112}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 110}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 109}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 106}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 114}]}, {"term": "Ischaemic stroke", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA (13.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 106}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 112}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 110}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 109}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 106}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 114}]}, {"term": "Tremor", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA (13.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 106}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 112}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 110}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 109}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 106}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 114}]}, {"term": "Ankle fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA (13.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 106}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 112}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 110}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 109}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 106}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 114}]}, {"term": "Multiple drug overdose intentional", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA (13.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 106}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 112}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 110}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 109}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 106}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 114}]}, {"term": "Alveolitis allergic", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA (13.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 106}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 112}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 110}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 109}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 106}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 114}]}, {"term": "Pulmonary fibrosis", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA (13.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 106}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 112}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 110}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 109}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 106}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 114}]}, {"term": "Non-cardiac chest pain", "organSystem": "General disorders", "sourceVocabulary": "MedDRA (13.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 106}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 112}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 110}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 109}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG005", "numAffected": 1, "numAtRisk": 106}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 114}]}, {"term": "Cholecystitis", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA (13.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 106}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 112}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 110}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 109}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 106}, {"groupId": "EG006", "numAffected": 1, "numAtRisk": 114}]}, {"term": "Hyperglycaemia", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA (13.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 106}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 112}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 110}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 109}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 106}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 114}]}, {"term": "Delusion", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA (13.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 106}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 112}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 110}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 109}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG005", "numAffected": 1, "numAtRisk": 106}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 114}]}, {"term": "Urinary retention", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA (13.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 106}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 112}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 110}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 109}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 111}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 106}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 114}]}, {"term": "Hypotension", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA (13.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 106}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 112}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 110}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 109}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 106}, {"groupId": "EG006", "numAffected": 1, "numAtRisk": 114}]}], "otherEvents": [{"term": "Hyperglycaemia", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA (13.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 28, "numAtRisk": 106}, {"groupId": "EG001", "numAffected": 19, "numAtRisk": 112}, {"groupId": "EG002", "numAffected": 13, "numAtRisk": 110}, {"groupId": "EG003", "numAffected": 19, "numAtRisk": 109}, {"groupId": "EG004", "numAffected": 9, "numAtRisk": 111}, {"groupId": "EG005", "numAffected": 8, "numAtRisk": 106}, {"groupId": "EG006", "numAffected": 1, "numAtRisk": 114}]}, {"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA (13.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 106}, {"groupId": "EG001", "numAffected": 6, "numAtRisk": 112}, {"groupId": "EG002", "numAffected": 5, "numAtRisk": 110}, {"groupId": "EG003", "numAffected": 8, "numAtRisk": 109}, {"groupId": "EG004", "numAffected": 4, "numAtRisk": 111}, {"groupId": "EG005", "numAffected": 7, "numAtRisk": 106}, {"groupId": "EG006", "numAffected": 6, "numAtRisk": 114}]}, {"term": "Diarrhoea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (13.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 106}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 112}, {"groupId": "EG002", "numAffected": 3, "numAtRisk": 110}, {"groupId": "EG003", "numAffected": 4, "numAtRisk": 109}, {"groupId": "EG004", "numAffected": 10, "numAtRisk": 111}, {"groupId": "EG005", "numAffected": 6, "numAtRisk": 106}, {"groupId": "EG006", "numAffected": 8, "numAtRisk": 114}]}, {"term": "Dyslipidaemia", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA (13.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 6, "numAtRisk": 106}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 112}, {"groupId": "EG002", "numAffected": 2, "numAtRisk": 110}, {"groupId": "EG003", "numAffected": 7, "numAtRisk": 109}, {"groupId": "EG004", "numAffected": 6, "numAtRisk": 111}, {"groupId": "EG005", "numAffected": 6, "numAtRisk": 106}, {"groupId": "EG006", "numAffected": 2, "numAtRisk": 114}]}, {"term": "Hypertension", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA (13.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 5, "numAtRisk": 106}, {"groupId": "EG001", "numAffected": 3, "numAtRisk": 112}, {"groupId": "EG002", "numAffected": 2, "numAtRisk": 110}, {"groupId": "EG003", "numAffected": 6, "numAtRisk": 109}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 111}, {"groupId": "EG005", "numAffected": 5, "numAtRisk": 106}, {"groupId": "EG006", "numAffected": 8, "numAtRisk": 114}]}, {"term": "Creatinine renal clearance decreased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA (13.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 4, "numAtRisk": 106}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 112}, {"groupId": "EG002", "numAffected": 4, "numAtRisk": 110}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 109}, {"groupId": "EG004", "numAffected": 6, "numAtRisk": 111}, {"groupId": "EG005", "numAffected": 5, "numAtRisk": 106}, {"groupId": "EG006", "numAffected": 9, "numAtRisk": 114}]}, {"term": "Upper respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (13.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 106}, {"groupId": "EG001", "numAffected": 3, "numAtRisk": 112}, {"groupId": "EG002", "numAffected": 3, "numAtRisk": 110}, {"groupId": "EG003", "numAffected": 4, "numAtRisk": 109}, {"groupId": "EG004", "numAffected": 3, "numAtRisk": 111}, {"groupId": "EG005", "numAffected": 8, "numAtRisk": 106}, {"groupId": "EG006", "numAffected": 2, "numAtRisk": 114}]}, {"term": "Nausea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (13.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 106}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 112}, {"groupId": "EG002", "numAffected": 3, "numAtRisk": 110}, {"groupId": "EG003", "numAffected": 4, "numAtRisk": 109}, {"groupId": "EG004", "numAffected": 6, "numAtRisk": 111}, {"groupId": "EG005", "numAffected": 3, "numAtRisk": 106}, {"groupId": "EG006", "numAffected": 6, "numAtRisk": 114}]}, {"term": "Hypertriglyceridaemia", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA (13.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 106}, {"groupId": "EG001", "numAffected": 3, "numAtRisk": 112}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 110}, {"groupId": "EG003", "numAffected": 3, "numAtRisk": 109}, {"groupId": "EG004", "numAffected": 6, "numAtRisk": 111}, {"groupId": "EG005", "numAffected": 6, "numAtRisk": 106}, {"groupId": "EG006", "numAffected": 1, "numAtRisk": 114}]}, {"term": "Nasopharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (13.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 106}, {"groupId": "EG001", "numAffected": 7, "numAtRisk": 112}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 110}, {"groupId": "EG003", "numAffected": 2, "numAtRisk": 109}, {"groupId": "EG004", "numAffected": 4, "numAtRisk": 111}, {"groupId": "EG005", "numAffected": 3, "numAtRisk": 106}, {"groupId": "EG006", "numAffected": 2, "numAtRisk": 114}]}, {"term": "Dyspepsia", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (13.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 106}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 112}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 110}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 109}, {"groupId": "EG004", "numAffected": 2, "numAtRisk": 111}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 106}, {"groupId": "EG006", "numAffected": 8, "numAtRisk": 114}]}, {"term": "Back pain", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA (13.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 106}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 112}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 110}, {"groupId": "EG003", "numAffected": 6, "numAtRisk": 109}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 111}, {"groupId": "EG005", "numAffected": 4, "numAtRisk": 106}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 114}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property."}, "pointOfContact": {"title": "Sr. VP, Clinical Science", "organization": "Takeda Global Research and Development Center, Inc.", "email": "clinicaltrialregistry@tpna.com", "phone": "800-778-2860"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24", "removedCountries": ["Chile", "Guatemala", "India", "Peru"]}, "conditionBrowseModule": {"meshes": [{"id": "D000003920", "term": "Diabetes Mellitus"}, {"id": "D000003924", "term": "Diabetes Mellitus, Type 2"}], "ancestors": [{"id": "D000044882", "term": "Glucose Metabolism Disorders"}, {"id": "D000008659", "term": "Metabolic Diseases"}, {"id": "D000004700", "term": "Endocrine System Diseases"}], "browseLeaves": [{"id": "M7115", "name": "Diabetes Mellitus", "asFound": "Diabetes Mellitus", "relevance": "HIGH"}, {"id": "M7119", "name": "Diabetes Mellitus, Type 2", "asFound": "Diabetes Mellitus, Type 2", "relevance": "HIGH"}, {"id": "M10053", "name": "Hypoglycemia", "relevance": "LOW"}, {"id": "M9994", "name": "Hyperglycemia", "relevance": "LOW"}, {"id": "M11639", "name": "Metabolic Diseases", "relevance": "LOW"}, {"id": "M25403", "name": "Glucose Metabolism Disorders", "relevance": "LOW"}, {"id": "M7862", "name": "Endocrine System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC18", "name": "Nutritional and Metabolic Diseases"}, {"abbrev": "BC19", "name": "Gland and Hormone Related Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000008687", "term": "Metformin"}, {"id": "C000520853", "term": "Alogliptin"}], "ancestors": [{"id": "D000007004", "term": "Hypoglycemic Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000054795", "term": "Incretins"}, {"id": "D000006728", "term": "Hormones"}, {"id": "D000006730", "term": "Hormones, Hormone Substitutes, and Hormone Antagonists"}, {"id": "D000054873", "term": "Dipeptidyl-Peptidase IV Inhibitors"}, {"id": "D000011480", "term": "Protease Inhibitors"}, {"id": "D000004791", "term": "Enzyme Inhibitors"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}], "browseLeaves": [{"id": "M11667", "name": "Metformin", "asFound": "Assessment", "relevance": "HIGH"}, {"id": "M247106", "name": "Alogliptin", "asFound": "Reflex", "relevance": "HIGH"}, {"id": "M10054", "name": "Hypoglycemic Agents", "relevance": "LOW"}, {"id": "M27905", "name": "Incretins", "relevance": "LOW"}, {"id": "M9789", "name": "Hormones", "relevance": "LOW"}, {"id": "M9788", "name": "Hormone Antagonists", "relevance": "LOW"}, {"id": "M27957", "name": "Dipeptidyl-Peptidase IV Inhibitors", "relevance": "LOW"}, {"id": "M19609", "name": "HIV Protease Inhibitors", "relevance": "LOW"}, {"id": "M14343", "name": "Protease Inhibitors", "relevance": "LOW"}, {"id": "M7951", "name": "Enzyme Inhibitors", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Hypo", "name": "Hypoglycemic Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "Infe", "name": "Anti-Infective Agents"}]}}, "hasResults": true}